<DOC>
	<DOCNO>NCT02299011</DOCNO>
	<brief_summary>The primary objective BIODEGRADE study evaluate clinical efficacy Orsiro drug-eluting stent compare Biomatrix drug-eluting stent , biodegradable polymer treatment all-comers ' coronary artery disease .</brief_summary>
	<brief_title>Comparison Biomatrix Orsiro Drug Eluting Stent</brief_title>
	<detailed_description>The rate in-stent restenosis percutaneous coronary intervention ( PCI ) decrease since launch drug-eluting stent ( DES ) . However , restenosis still remain problem since PCI perform complex , calcify , tortuous tough lesion . Furthermore , still controversy whether DES thrombogenic bare metal stent ( BMS ) inflammation relate polymer coat delayed vessel heal due elute drug despite reduced restenosis . Therefore , work aim reduce restenosis thrombotic event still on-going field interventional cardiology , rush various third generation DES `` biodegradable polymer '' . Recently , Orsiro hybrid DES ( Biotronik AG , Bulach , Switzeland ) develop . The Orsiro DES incorporate optimally combine two kind polymer onto thin cobalt-chromium backbone ( 60um ) compare earlier type DES . The BIOlute® active component bioabsorbable polymer matrix combine anti-proliferative drug , sirolimus , release control manner leave PROBIO® coat stent long-term . The PROBIO® passive coating encapsulate stent eliminates interaction metal stent surround tissue . To date , Orsiro stent show excellent result term late lumen loss 9 month first-in-man single arm trial compare historical result DES ( BIOFLOW-I trial ) , RCT non-inferiority design , compare late lumen loss 9 month Orsiro versus everolimus-eluting stent ( Xience prime® ) ongoing ( BIOFLOW-II trial ) . However , trial compare Orsiro stent versus Biomatrix stent ( Biosensors Inc , Newport Beach , CA , USA ) . This multicenter , randomize , open label , parallel arm study evaluate whether innovative new generation stent , Orsiro hybrid DES , non-inferior third generation stent , Biomatrix stent , term 18 month late lumen loss .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>1 . General Inclusion Criteria 1 . Subject must least 18 year age . 2 . Subject able verbally confirm understandings risk , benefit treatment alternative receive Biomatrix flex stent Orsiro stent , he/she his/her legally authorize representative provide write informed consent prior study related procedure . 3 . Subject must significant lesion ( &gt; 50 % visual estimate ) coronary artery , venous arterial bypass graft . 4 . Subject must evidence myocardial ischemia ( e.g. , stable , unstable angina , recent infarction , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) . In subject diameter stenosis &gt; 70 % , evidence myocardial ischemia document . 2 . Angiographic Inclusion Criteria 1 . Target lesion ( ) must locate coronary artery , venous arterial bypass graft diameter ≥ 2.5 mm ≤ 4.5 mm . 2 . Target lesion ( ) must amenable percutaneous coronary intervention . 1 . The patient know hypersensitivity contraindication follow medication : Heparin , Aspirin , Clopidogrel , Cilostazol , Prasugrel , Ticagrelor , Biolimus , Sirolimus , Contrast medium ( Patients document sensitivity contrast medium effectively premedicated steroid diphenhydramine [ e.g . rash ] may enrol . Those true anaphylaxis prior contrast medium , however , enrol . ) 2 . Systemic ( intravenous ) Biolimus Sirolimus use within 12 month . 3 . Female childbearing potential , unless recent pregnancy test negative , possibly plan become pregnant time enrollment study . 4 . History bleed diathesis , know coagulopathy ( include heparin induce thrombocytopenia ) , abnormal hemogram ( Hb &lt; 10g/dL PLT count &lt; 100,000/μL ) refuse blood transfusion 5 . Patients severe LV systolic dysfunction ( LVEF &lt; 25 % ) cardiogenic shock 6 . Gastrointestinal genitourinary bleeding within prior 2 month , major surgery within 2 month . 7 . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) . 8 . Patients actively participate another drug device investigational study , complete primary endpoint follow period . 9 . Symptomatic heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Biomatrix drug elute stent</keyword>
	<keyword>Orsiro drug elute stent</keyword>
	<keyword>Coronary artery disease</keyword>
</DOC>